Fovista combined with Eylea, Avastin shows no benefit over anti-VEGF monotherapy

Fovista anti-PDGF therapy combined with Eylea or Avastin anti-VEGF therapies failed to show superiority to anti-VEGF monotherapy in its phase 3 clinical trial for the treatment of wet age-related macular degeneration, Ophthotech Corp. announced.Subjects in the international, multicenter, randomized, double-masked, phase 3 study who received Fovista (pegpleranib) in combination with Eylea (aflibercept, Regeneron) or Avastin (bevacizumab, Genentech) gained a mean of 9.42 letters of vision, compared to 9.04 letters for those receiving either of the monotherapies, according to a company press release.